Stock Screener
Stock Research
Market Indexes
Precious Metals
Energy
Commodities
Interest Rates
Economy
Global Metrics

Synaptogenix Gross Margin 2020-2025 | TAOX

Current and historical gross margin for Synaptogenix (TAOX) over the last 10 years. The current gross profit margin for Synaptogenix as of March 31, 2025 is %.
  
Synaptogenix Gross Margin Historical Data
Date TTM Revenue TTM Gross Profit Gross Margin
Sector Industry Market Cap Revenue
Medical MED-BIOMED/GENE $0.012B $0.000B
Synaptogenix Inc. is an emerging biopharmaceutical company. It focused on developing therapies for neurodegenerative diseases. The company's lead therapeutic candidate consist Bryostatin-1. Synaptogenix Inc. is based in NEW YORK.
Stock Name Country Market Cap PE Ratio
Anglo American (NGLOY) United Kingdom $35.835B 0.00
Lancaster Colony (MZTI) United States $4.963B 26.75
International Game Technology (BRSL) United Kingdom $3.465B 26.39
Eyenovia (HYPD) United States $0.041B 0.00
JVSPAC Acquisition (HBNB) Hong Kong, SAR China $0.026B 0.00
Finnovate Acquisition (SCAG) Cayman Islands $0.026B 0.00
KWESST Micro Systems (DFSC) Canada $0.006B 0.00